NCT06221774View on ClinicalTrials.gov

Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2025

Conditions
Clear Cell Renal CarcinomaUrothelial CarcinomaMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

TT-00420 + Toripalimab

TT-00420 tablets in combination with Toripalimab injection

Trial Locations (1)

210000

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06221774 - Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | Biotech Hunter | Biotech Hunter